These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 28888219

  • 41. Concomitant assessment of rivaroxaban concentration and its impact on thrombin generation.
    Bloemen S, Zwaveling S, Mullier F, Douxfils J.
    Thromb Res; 2019 Dec; 184():8-15. PubMed ID: 31677449
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Novel assay based on diluted prothrombin time reflects anticoagulant effects of direct oral factor Xa inhibitors: Results of multicenter study in Japan.
    Ieko M, Ohmura K, Naito S, Yoshida M, Sakuma I, Ikeda K, Ono S, Suzuki T, Takahashi N.
    Thromb Res; 2020 Nov; 195():158-164. PubMed ID: 32707358
    [Abstract] [Full Text] [Related]

  • 44. Coagulation Test Interpretation in a Patient Taking Direct Oral Anticoagulant Therapy.
    Sholzberg M, Xu Y.
    JAMA; 2018 Oct 09; 320(14):1485-1486. PubMed ID: 30242329
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Thrombin Generation and other hemostatic parameters in patients with atrial fibrillation in use of warfarin or rivaroxaban.
    Duarte RCF, Rios DRA, Figueiredo EL, Caiaffa JRS, Silveira FR, Lanna R, Alves LCV, Martins GL, Reis HJ, Reis EA, Ferreira CN, Sternick EB, Campos FMF, das Graças Carvalho M.
    J Thromb Thrombolysis; 2021 Jan 09; 51(1):47-57. PubMed ID: 32377955
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability.
    Siguret V, Abdoul J, Delavenne X, Curis E, Carlo A, Blanchard A, Salem JE, Gaussem P, Funck-Brentano C, Azizi M, Mismetti P, Loriot MA, Lecompte T, Gouin-Thibault I.
    J Thromb Haemost; 2019 Oct 09; 17(10):1670-1682. PubMed ID: 31215111
    [Abstract] [Full Text] [Related]

  • 52. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E.
    Thromb Haemost; 2010 Apr 09; 103(4):815-25. PubMed ID: 20135059
    [Abstract] [Full Text] [Related]

  • 53. Rivaroxaban Levels in Patients' Plasmas are Comparable by Using Two Different Anti Xa Assay/Coagulometer Systems Calibrated with Two Different Calibrators.
    Martinuzzo ME, Duboscq C, Lopez MS, Barrera LH, Vinuales ES, Ceresetto J, Forastiero RR, Oyhamburu J.
    Clin Lab; 2018 Jun 01; 64(6):1091-1095. PubMed ID: 29945328
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Circadian variations in laboratory measurements of coagulation assays after administration of rivaroxaban or warfarin in patients with nonvalvular atrial fibrillation.
    Hitaka Y, Ogawa M, Zhang B, Goto S, Nagata Y, Morii J, Imaizumi S, Yasuda T, Matsumoto N, Matsunaga A, Saku K.
    J Cardiol; 2016 Dec 01; 68(6):529-535. PubMed ID: 26987789
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.